SELLAS Life Sciences (SLS) Total Liabilities (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Total Liabilities for 9 consecutive years, with $10.6 million as the latest value for Q3 2024.
- Quarterly Total Liabilities fell 10.91% to $10.6 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $10.6 million through Sep 2024, down 10.91% year-over-year, with the annual reading at $14.2 million for FY2023, 11.79% down from the prior year.
- Total Liabilities for Q3 2024 was $10.6 million at SELLAS Life Sciences, down from $12.2 million in the prior quarter.
- The five-year high for Total Liabilities was $18.1 million in Q4 2020, with the low at $5.9 million in Q4 2021.
- Average Total Liabilities over 5 years is $12.7 million, with a median of $12.2 million recorded in 2024.
- The sharpest move saw Total Liabilities tumbled 67.23% in 2021, then soared 171.46% in 2022.
- Over 5 years, Total Liabilities stood at $18.1 million in 2020, then crashed by 67.23% to $5.9 million in 2021, then skyrocketed by 171.46% to $16.1 million in 2022, then decreased by 11.79% to $14.2 million in 2023, then fell by 25.23% to $10.6 million in 2024.
- According to Business Quant data, Total Liabilities over the past three periods came in at $10.6 million, $12.2 million, and $14.8 million for Q3 2024, Q2 2024, and Q1 2024 respectively.